According to The Australian, Zurich Insurance Group is no longer in the running to acquire NIB’s travel insurance division, easing potential regulatory headaches in what has been one of the most closely watched insurance sales of the year.
The business, which is being marketed through investment bank Jarden, had initially drawn interest from as many as seven potential suitors. Zurich was long regarded as a frontrunner given its ownership of Cover-More, one of the largest players in the sector. But industry sources say the Swiss insurer has stepped back from the bidding process, leaving others including Allianz and Hollard as leading contenders.
NIB first confirmed in May that it was conducting a strategic review of its travel insurance arm. In August, the group reiterated that a decision was imminent, telling investors that an outcome was expected within the financial year.
The business operates under well-recognised brands such as NIB Travel, World Nomads and Travel Insurance Direct. While sales in June reached their strongest monthly level in two years, profitability has been pressured. Underlying operating profit for the year to June fell 17.3 per cent to $6.7 million, even as gross written premium edged 1.7 per cent higher to $170.7 million.
Executives highlighted tighter cost control, with operating expenses down 6.7 per cent, and reported operating income of $88.1 million. The review will determine whether the company exits travel altogether, following more than a decade of expansion in the segment.
Australia’s travel insurance market generates about $1.8 billion in annual revenue and close to $200 million in net profit. Allianz leads the sector with a 25 per cent share, followed closely by Zurich at 24 per cent. NIB holds 8.4 per cent, with IAG controlling a smaller 2.4 per cent slice, according to IBISWorld figures.
While demand has rebounded to pre-pandemic levels, rising reinsurance costs and elevated claims payouts continue to weigh on margins. Industry analysts say these pressures have accelerated consolidation, with scale becoming critical for profitability.
Sources close to the process expect the NIB business could command a price in the vicinity of $200 million. If realised, the sale would mark a significant reshaping of the competitive landscape, with Allianz and Hollard both positioned to lift their presence in direct-to-consumer channels.
NIB’s decision to explore an exit reflects a broader recalibration of its portfolio, with the health insurer concentrating capital on areas considered core to long-term growth.
For now, Zurich’s withdrawal reduces concerns of an overly dominant player emerging from the process – but with multiple global insurers still circling, the outcome will be closely watched across Australia’s insurance industry.
